Sensei Biotherapeutics cuts workforce 46%, extends cash runway into Q2 2026; Q3 net loss $7.3M

Sensei Biotherapeutics, Inc.

2024-Q3 EPS reported -$0.89

Net loss $7.3M for Q3 2024 vs $7.1M year ago; cash & securities $47.0M as of Sept 30.
Organizational restructuring: closing Rockville research site, reducing workforce ~46%, focusing on SNS-101.
SNS-101 Phase 1/2 dose expansion clinical data expected in H1 2025; enrollment ~50% complete.
Appointed Josiah Craver as SVP Finance, principal financial and accounting officer in September.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.